GESTIÓN EN SALUD PÚBLICA: FDA approves ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia | FDA

viernes, 27 de mayo de 2022

FDA approves ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia | FDA

FDA approves ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)